CD19 and graft versus host disease: In clinical settings, UCART19, the first allogeneic CD19-targeting CAR-T cell therapy incorporating TRAC disruption via TALENs, reduced GvHD incidence to grade 1 skin GvHD in 10% and 8% of patients in 2020 and 2022, respectively [66].